IN THE SPECIFICATION

Please amend paragraph 5 as follows:

In one embodiment, a method of treating a human in need of cancer treatment comprises administering a composition comprising greater than 0.5 weight percent of a phytoestrogen based on the total weight of the composition, wherein the phytoestrogen is:

wogonin, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by formula (1)

wherein R^1 is hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 alkoxy; R^2 is hydrogen, C_1 - C_6 alkyl, or C_2 - C_6 acyl; R^3 and R^4 are independently hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl; one of R^5 or R^6 is hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl, wherein the other of R^{5A} or R^{5B} is

wherein R^7 - R^{11} are independently hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl; and wherein at least four of R^3 - R^{11} are hydrogen;

isoliquiritigenin, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by the formula (2)

$$R^{10}$$
 R^{16}
 R^{15}
 R^{19}
 R

wherein R^{11} - R^{14} are independently hydrogen or C_1 - C_6 alkyl; R^{15} - R^{20} are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl, wherein at least three of R^{15} - R^{20} are hydrogen;

coumestrol, its pharmaceutically acceptable esters and salts, and its selectively substituted analogs represented by the formula (3)

$$R^{21}O$$
 R^{24}
 R^{25}
 R^{26}
 R^{26}
 R^{26}
 R^{27}
 R^{28}
 R^{27}
 R^{28}
 R^{29}
 R^{29}

wherein R^{21} and R^{22} are independently hydrogen or C_1 - C_6 alkyl; and R^{23} - R^{28} are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl, wherein at least three of R^{23} - R^{28} are hydrogen;

a prenyl isoflavonoid represented by formula (4)

$$R^{30}$$
 R^{30}
 R^{30}

wherein R^{30} and R^{31} are independently hydrogen or 3-methyl-2-butenyl, with the proviso that at least one of R^{31} and $R^{32}R^{33}$ is 3-methyl-2-butenyl; R^{29} and R^{32} are independently hydrogen or C_1 - C_6 alkyl; and R^{33} - R^{37} are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl; and wherein at least two of R^{33} - R^{37} are hydrogen;

or a combination comprising one or more of the foregoing phytoestrogens.

Please amend paragraph 55 as follows:

The phytoestrogen can comprise a prenyl flavonoid such as, for example, 6-prenylnarignin, 8-prenylnaringenin, and 6,8-diprenylnaringenin. Suitable prenyl isoflavonoids are represented by Formula

$$R^{30}$$
 R^{31}
 R^{34}
 R^{35}
 R^{34}
 R^{35}
 R^{34}
 R^{35}
 R^{35}
 R^{36}
 R^{31}
 R^{35}
 R^{35}
 R^{35}
 R^{35}
 R^{35}
 R^{35}
 R^{35}
 R^{35}

4

CSO-0001-P

wherein R^{30} and R^{31} are independently hydrogen or 3-methyl-2-butenyl, with the proviso that at least one of R^{31} and R^{31} R^{33} is 3-methyl-2-butenyl; R^{29} and R^{32} are independently hydrogen or C_1 - C_6 alkyl; and R^{33} - R^{37} are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_2 - C_6 acyl; and wherein at least two of R^{33} - R^{37} are hydrogen.